- Clone:
- REAL172
- Type of antibody:
- Releasable antibodies, Primary antibodies, Recombinant antibodies
- Applications:
- FC Glossary
- Select a conjugate:
- Select a size:
Related products for CD101 Antibody, anti-mouse, REAlease®
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
Comparison of staining pattern on non-fixed and fixed cells using CD101 (REAL172). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Clone REAL172 is an antibody fragment derived from the full CD101 antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAlease Complex to bind markers with high avidity.
Clone REAL172 recognizes the mouse CD101 antigen, a type I transmembrane glycoprotein also known as Immunoglobulin superfamily member 2 (IgSF2) or V7. CD101 is expressed on monocytes, granulocytes, dendritic cells (DCs), and activated T cells. In humans CD101 inhibits the proliferative response of T cells to allogeneic cells or immobilized anti-CD3 antibody, suggesting that engagement of CD101 can antagonize TCR/CD3-mediated lymphocyte activation. Moreover, human peripheral CD8+ T cells that express CD101 and CD103 display suppressive function after activation with intraepithelial cells or placental trophoblasts. In addition to its role on T cells, triggering CD101 on human cutaneous DC inhibits T cell proliferation via interleukin 10 (IL-10) production, suggesting that the CD101 molecule may be involved in tolerance induction. Studies in mice showed that cell surface expression of CD101 is highly correlated with functional suppressor activity within CD4+CD25+ regulatory T cells both in vitro and in vivo.
The REAlease Kits consist of the respective fluorochrome-conjugated REAlease Complexes and the REAlease Support Kit for removal of the REAlease Complexes and optional relabeling with different fluorochrome-conjugated REAlease Complexes.
EWI-101, Gm1016, Gm734, IGSF2
Technical specifications
To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.
Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.
- Fernandez, I. et al. (2007) CD101 surface expression discriminates potency among murine FoxP3+ regulatory T cells. J Immunol 179 (5): 2808-2814
- Mohammed, J. P. et al. (2011) Identification of CD101 as a susceptibility gene for Novosphingobium aromaticivorans-induced liver autoimmunity. J Immunol 187 (1): 337-349
- Penha-Gonçalves, C. et al. (2003) Identification of a structurally distinct CD101 molecule encoded in the 950-kb Idd10 region of NOD mice. Diabetes 52 (6): 1551-1556